Teva gives up on (former) partner's inhaler; Neos orally disintegrating tablet performs well in Phase III;

> Alexza Pharmaceuticals ($ALXA) is reacquiring the U.S. rights to its Adasuve inhalation powder from Teva ($TEVA). The company aims to find a new partner next year for the product to treat central nervous system conditions. It's delivered into the lungs via the Staccato hand-held inhaler. More

> Neos Therapeutics said its extended-release, orally disintegrating tablet for ADHD performed better than placebo in a Phase III trial. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.